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Fibromyalgia (FM) is a contested illness with ill-defined boundaries. There is no clearly defined cut-point that 
separates FM from non-FM. Diagnosis of FM has been faced with several challenges that occur, including 
patients’ health care-seeking behavior, symptoms recognition, and FM labeling by physicians. This review 
focuses on important but less visible factors that have a profound influence on under- or over-diagnosis of 
FM. FM shows different phenotypes and disease expression in patients and even in one patient over time. 
Psychosocial and cultural factors seem to be a contemporary ferment in FM which play a major role in physician 
diagnosis even more than having severe symptom levels in FM patients. Although the FM criteria are the only 
current methods which can be used for classification of FM patients in surveys, research, and clinical settings, 
there are several key pieces missing in the fibromyalgia diagnostic puzzle, such as invalidation, psychosocial 
factors, and heterogeneous disease expression. Regarding the complex nature of FM, as well as the arbitrary 
and illusory constructs of the existing FM criteria, FM diagnosis frequently fails to provide a clinical diagnosis 
fit to reality. A physicians’ judgment, obtained in real communicative environments with patients, beyond the 
existing constructional scores, seems the only reliable way for more valid diagnoses. It plays a pivotal role in 
the meaning and conceptualization of symptoms and psychosocial factors, making diagnoses and labeling of 
FM. It is better to see FM as a whole, not as a medical specialty or constructional scores. (Korean J Pain 
2018; 31: 147-54)
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INTRODUCTION
Fibromyalgia (FM) is a contested illness where there is a 
considerable controversy in its nature, existence, assess-
ment, and diagnosis [1-3]. There are several challenges in 
FM diagnosis that occur across patients’ behavior in medi-
cal care seeking, to the meaning and conceptualization of 
symptoms by clinicians, and finally in making a diagnosis 
and the labeling of FM. 
This review has focused on important but less visible 
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factors that influence profoundly on under- or over-diag-
nosis of FM by physicians. We hope this review creates a 
new gate to a holistic and real understanding of FM diag-
nosis beyond existing arbitrary and constructional scores. 
MAIN BODY 
1. Fuzzy boundaries of fibromyalgia with broad and 
time-changing phenotypes
Chronic widespread pain, sleep problems or unrefreshing 
sleep, physical exhaustion, and cognitive difficulties are the 
core symptoms of FM [4,5]. However, most patients diag-
nosed with FM report a wide range of additional somatic 
and psychological symptoms [4]. It has fuzzy boundaries 
that are cross-linked to other illness (such as psycho-
logical disorders) as subsets, mistaken diagnosis and co-
morbid conditions [2]. There are more confusing issues 
when we review our knowledge about FM neurobiology, ill-
ness definition, and accepted diagnostic criteria.
Although not yet fully understood, the new concept 
suggests that FM is a heterogeneous condition which likely 
has multiple potential etiologies [6]. It is important to not 
consider FM as ‘yes’ or ‘no’ but rather as the end of a 
continuum [6-8]. On the one end of this continuum is a 
purely peripherally driven painful condition and the other 
end of the continuum is when pain is nearly completely the 
result of altered central augmentation [6]. 
In fact, many clinical researches suggest that various 
individuals with chronic pain, including FM, are at various 
points in this continuum [9,10]. Thus, some patients may 
have stronger peripheral than central components, some 
mixed components, and many have stronger central 
components. Consequently, FM Patients may present with 
different phenotypes according to their different underlying 
neurobiology [6].
Furthermore, it is also debated whether patients 
maintain their characteristic phenotype and disease ex-
pression with time, or whether disease expression changes 
[11]. It is not surprising that an individual FM core symptom 
may emerge or decline as a predominant symptom over 
time [12]. 
Due to diversity of symptoms presentation and severity 
over time, it is possible that an individual with FM seeks 
medical help and is diagnosed with the FM label at one 
time, and the same patient, at another time, is given a 
diagnostic label that merely connotes more local com-
plaints, such as chronic low back pain, headache, or tem-
poromandibular joint disorder, irritable bowel syndrome 
(IBS), and so on [6,13]. It seems that some FM core symp-
toms diminish or fade over time [14], or patients do not 
mention actively in their core symptoms which may be 
non-significant or may be missed by the clinician. 
Core symptom variation both within a patient over 
time as well as between patients in the setting of etiologic 
and symptom heterogeneity produces considerable per-
plexity in FM diagnosis, even in hands of experts. The 
clinicians who are familiar with FM contend that “they can 
recognize FM”, but experts still debate practical clinical di-
agnostic criteria [11,15]. So, the precise diagnosis in an in-
dividual patient may be elusive, with symptoms present for 
years leading to many health care encounters and diag-
nostic delay [16]. 
2. Patients and physicians’ confounding factors in FM 
diagnosis
The substantial role for psychosocial and environmental 
determinants in FM patients capturing and diagnosis can-
not be denied [17]. It was demonstrated that having the 
severe core symptoms that define FM is not essential to 
receiving an FM diagnosis. Rather, demographic and social 
disadvantage appears to be more important than symptom 
severity in making FM clinical diagnosis by clinicians [17]. 
For obtaining an FM diagnosis, symptomatic persons must 
seek medical care from clinicians and those clinicians must 
interpret and label the described symptoms as being FM. 
A patient cannot obtain an FM diagnosis unless they want 
to see a clinician who is willing to make that diagnosis. 
So, clinical diagnosis of FM patients is necessarily con-
founded by patient’s health care seeking behavior and 
clinical selection [18]. 
Furthermore, in a clinical setting, physicians’ beliefs 
and biases influence FM diagnosis [2]. All FM assessments 
are subjective and there is no clear gold standard for FM 
diagnosis [19]. The constellation of severe symptoms can 
be clinically interpreted and diagnosed in many different 
ways, perhaps influenced by clinicians [20]. This leads to 
a large number of apparently over- and under-diagnosed 
subjects in clinical settings [2,17]. On one hand, a diag-
nosis of FM can legitimize vague and difficult symptoms, 
allowing entrée into official diagnosis or providing a way 
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toward official disability status. So, resultantly, millions of 
people may be given a FM diagnosis without satisfying the 
severity cutoff of FM diagnosis [2,21]. 
On the other hand, it appears that many clinicians, 
when faced with the opportunity to diagnose FM may miss 
making such a diagnosis. This action may be related to 
the complexity and diversity of FM symptoms, the pres-
ence of other medical diagnoses, a lack of knowledge; or 
a disagreement about the nature and meaning of symp-
toms and how they should be interpreted [18,22]. So, it is 
not so surprising to see patients who have gone from doc-
tor to doctor and who underwent multiple diagnostic tests 
and received alternative diagnoses such as lupus eryth-
ematous, rheumatoid arthritis, non-specific “arthritis” and 
malingering [16,23]. 
FM patients may experience and mention some level 
of lack of understanding or discounting by their clinicians, 
family, or other people that interact with them. The term 
“invalidation” is used to describe the patients’ perception 
that their illness and symptoms is not recognized by their 
social environment [24]. Although invalidation is not ex-
clusive to FM patients and also affects other rheumatic 
diseases, it most often perceived and expressed by FM pa-
tients [25,26]. Practicing clinicians are often confronted 
with a high prevalence of invalidation in FM patients. In 
recent years, some researchers have suggested that pa-
tients’ perception of invalidation by clinicians could be a 
clue for the diagnosis of FM. In fact, it would certainly be 
helpful to be clear whether invalidation assessment may be 
useful for diagnosis or classification of FM [27].
Resultantly, it seems that both patients’ behavior and 
clinical symptoms as well as physicians’ symptom inter-
pretation, beliefs, invalidation, or intimacy with patients 
can clearly influence whether or not an FM diagnosis is 
given.
3. Application of the FM classification criteria in our 
diagnostic lexicon 
The existing FM classification criteria has clearly altered 
and introduced a more precise case definition of FM in the 
recent decades. The recent criteria for the diagnosis of FM 
are clearly a steps towards a better understanding of this 
condition and are currently used for survey and clinical 
purposes. However, it seems much more effort must be 
made in this direction. The existing diagnostic criteria 
don’t seem to cover the broad heterogeneity and variation 
in symptoms and severity.
Regarding the intuitive complexity of the nature of FM, 
as well as the presence of these broad confounding factors 
in diagnosis, using a more valid diagnostic instrument 
seems essential. It seems that FM is better conceptualized 
as a symptom and etiological continuum rather than as a 
discreet dichotomous entity inferred by existing criteria 
[8,28-31]. 
No clear distinguishing point exists where FM stops 
being FM and becomes some other illness with more lo-
calized complaints, or no illness at all [18]. This raises a 
fundamental question about how diagnostic labeling should 
be applied according to the diagnostic criteria, because 
one patient may be labeled as FM on one occasion and 
non-FM on another. FM patients often move on this spec-
trum, occasionally toward a typical FM phenotype and at 
other times toward a normal phenotype [12], probably due 
to the effects of certain psychological, environmental, or 
other unknown factors. But, it is important to note that 
each patient is the same person in regards to genotype, 
neurobiology, and other risk factors. 
Although, as mentioned before, psychological and en-
vironmental, or socio-cultural factors also play an im-
portant role in presentation, recognition and capturing, or 
even of labeling FM cases [17,18], there is no place for 
these issues in the FM criteria. In other words, these fac-
tors undoubtedly influence diagnosis of FM and are even 
more important than symptom severity in the probability 
of receiving an FM diagnosis by medical healthcare pro-
viders [17]. 
On the other hand, physicians will differ in their inter-
pretation of patient complaints and also the severity of 
symptoms. A physician both records the complaint as pre-
sented by the patient, and also assesses the validity of the 
symptom report which the latter does not provide by the 
existing criteria. It is likely that some persons with FM may 
exaggerate subjective symptoms for reasons of secondary 
gain such as obtaining disability payments [32]. 
So, full clinical evaluation such as assessment of day- 
to-day activities, information from all treating healthcare 
professionals, and careful observation during assessment 
for evidence of discrepancies in clinical findings should still 
remain the standard of patient evaluation and diagnosis, 
rather than relying on differently interpreted or perceived 
FM criteria items.
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Regarding both the above-mentioned issues and some 
other points in criticizing the existing criteria (see 
“Arbitrary and illusory constructs of the existing FM cri-
teria”), it seems these criteria have not met expectations. 
There is a critical question which deals with the existing 
criteria: to what extent are the symptom-based and arbi-
trary constructs of the existing FM criteria suitable as di-
agnostic instruments? Although these criteria have in-
corporated most core symptoms of FM, there appears to 
remain a long and hard path to achieve a holistic and in-
tuitive instrument for FM diagnosis. 
In Egolff view, “No specialist in internal medicine would 
be likely to confuse the New York Heart Association (NYHA) 
criteria for quantifying dyspnea in heart failure with the 
diagnosis of the underlying cardiomyopathy” [13]. In other 
words, use of symptom scores and cutoff points are not 
the type of instrument needed or suitable for the clinical 
diagnosis of diseases. It seems that the just symp-
tom-based approach for diagnosis of disease was subject 
to criticism from the very beginning [13,33]. This approach 
results in a failure to provide a diagnostic instrument fit 
for clinical purposes [7]. 
Diagnosis of FM is discretionary and patient symptoms 
level, psychosocial factors, and external societal factors 
influence that discretion [2]. It is wise to quote George 
Ehrlich’s sentence: “When one has tuberculosis, one has 
tuberculosis, whether or not it is diagnosed, but “no one 
has FM until it is diagnosed” [34]. So, diagnostic labeling 
in FM must be used with caution and discretion [17,34]. 
This double-edged tool can have both beneficial and 
harmful effects. On the one hand, delay in labeling can re-
sult in excessive testing, inappropriate treatment, and 
consequently economic burden on the healthcare system 
and frustration for patients and their families. On the other 
hand, extensive use of FM diagnosis as an explanation of 
mild-to-moderate levels of symptoms or illness impact has 
likely led to substantial harm to patient and societal costs 
[17]. 
Finally, at the present time, no matter where we put 
FM criteria in our diagnostic lexicon, undoubtedly, these 
criteria are the only current methods which can be used 
for classification of FM patients in surveys, research, and 
clinical settings. However, there are several missing pieces 
in the diagnostic puzzle of FM. Until receiving more accu-
rate data about diagnostic methods, it seems that there 
is no way except the discretionary policy of clinicians for 
the diagnosis and labeling of this disorder. Physicians’ 
judgment obtained in a real communicative environment 
with patients, beyond the existing constructional scores, 
seems the only reliable way for more valid diagnoses. Much 
more effort is required to identify the many missing pieces 
of the FM puzzle, which seem to cause and perpetuate this 
medical problem. 
4. Substantial role of psychosocial factors in FM diagnosis
Data obtained from large population studies has provided 
new insight into FM diagnosis in the general population and 
clinical settings [17,18]. It revealed a fundamental role for 
psychosocial and cultural factors in the diagnostic accept-
ability of FM. These studies showed that having severe 
symptoms which define FM showed substantially less influ-
ence on how patients received FM diagnosis by physicians. 
Rather, health care-seeking behavior and clinical se-
lection, as well as social and cultural factors are more im-
portant in physician diagnosis. So, 73% of the population 
who had enough severe symptoms to meet a cri-
teria-based diagnosis did not receive a clinical diagnosis 
of FM [17]. On the other hand, 75% of persons in the US 
population reporting a clinician diagnosis of fibromyalgia 
did not satisfy FM criteria [18]. This observation showed 
the large numbers of apparently over- and under-diag-
nosed subjects. In this regard, demographic factors and 
social disadvantage appears to be more important than 
symptom reporting in predicting FM diagnosis [17]. It 
seems the under- and over-diagnosis of clinical FM may 
be at least partly related to the possible influence of social 
and cultural factors. 
To have clinical diagnosis and to legitimize the illness, 
which does not have any visible sign of disease, a patient 
must receive an insurance diagnosis by physician [35]. In 
developed countries, FM patients often take an active role 
in their diagnosis, recognizing their poly-symptomatic dis-
tress (PDS) as FM and seeking clinical care for con-
firmation and treatment [21].
As a result, the diagnosis of FM has been extended 
beyond expectations and consequently has lead to an 
over-diagnosis of this illness [18]. Self-reported clinical 
FM diagnosis appears to be increased by programs for 
clinical awareness, through educational activities for clini-
cians, academic research, patient advocacy, and direct- 
to-patient advertising, much of which has been financed 
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by the pharmaceutical industry [1,21,36].
In contrast, the substantial numbers of under-diag-
nosed FM cases showed high level of invalidation of pa-
tients by their medical care providers and social environ-
ment. Furthermore, many physicians express frustration 
directed not only at the FM issue, but also at patients. 
They will not see patients that are referred to them for 
suspicious FM and others will only see the patient for a 
one-time assessment to exclude other disorders [34]. This 
misunderstanding can also be seen in family members or 
other people interacting with patients [24,27]. It seems 
that this high level of invalidation may be related to the 
great psychological distress expressed by FM patients and 
also to inherently invisible FM symptoms and to socio-
cultural factors [25].
Furthermore, the surprising data about substantial 
discordance between physician-based and criteria-based 
diagnosis raise a simple but essential question concerning 
to what extent we are permitted to confine all of our dis-
cretion about symptoms’ meaning and severity into the 
scores or criteria construction. Undoubtedly, the answer to 
this question can be an important step toward a more real 
diagnosis of FM. 
5. Arbitrary and illusory constructs of the existing FM 
criteria
In 1990, The ACR committee found that the presence of 
widespread pain combined with at least 11 out of 18 tender 
points best separated patients with fibromyalgia from con-
trols that led to development of the 1990 ACR criteria [28]. 
However, tender point examination was hard for most 
non-rheumatologists to perform [20,29]. Numerous con-
cerns were raised on the reliability and validity of the ten-
der points in the clinical setting, which eventually led to 
stopping their use in clinics [20]. 
So, the 2010 ACR preliminary diagnostic criteria pro-
posed to address numerous problems with the 1990 ACR 
criteria [29]. The ACR 2010 criteria not only eliminated 
tender points, they also changed the case definition of FM 
to an illness characterized by self-reported, multiple pain-
ful regions (0-19 WPI) and additional key symptoms, such 
as problems with fatigue, sleep, cognition, and the extent 
of somatic symptom reporting [29]. 
The change in definition from 1990 to 2010 gave an 
important role to non-pain symptoms in FM diagnosis. 
Furthermore, there were a small proportion of patients 
whom clinicians diagnosed as having FM but who did not 
satisfy the 1990 criteria because of having either ＜ 11 ten-
der points or slightly less than the full ACR 1990 definition 
of widespread pain [29]. These cases were recognized sim-
ply by the 2010 ACR criteria. Moreover, another remark-
able achievement of the 2010 criteria was introducing of 
the Poly-symptomatic distress (PSD) scale [7]. With the 
PSD Scale, dichotomizing diagnosis and distress becomes 
less important [7,20]. 
Because it shows where the patient is on the con-
tinuum of distress or symptoms, as well as how far the 
patient is from the positive/negative dividing line [30]. 
Although the 2010 ACR criteria mapped out FM as a di-
mensional or continuum disorder, this concept did not ap-
ply completely. There is still a cut point for FM diagnosis 
in the PSD or the 2010 ACR criteria where patients are 
classified as FM versus non-FM. Hence this fact raises a 
fundamental question about how much difference there 
truly is between patients on different side of the cut point. 
In fact, the boundaries of FM are not well defined and 
there is no clearly defined cut point that separates FM 
from non-FM [2,30]. Moreover, all assessments are sub-
jective, and both physicians and patients might differ in 
their assessment of severity [20]. So, this makes dis-
tinguishing cases and non-cases difficult and arbitrary [1]. 
Additionally, it seems that dropping the tender point 
concept is not only the main advantage of the ACR 2010 
criteria but also their greatest drawback [13]. The 2010 
criteria study showed that muscle tenderness was one of 
the most important variables classifying cases and 
non-cases of FM, although tenderness was not used in the 
final formulation of the criteria [29]. Numerous previous 
studies confirm that the feature of hyperalgesia is a crucial 
and intuitive characteristic of FM [1,3,37]. Although the 
majority of experts agree that tender points’ examination 
and interpretation is difficult and may miss the intended 
target [20,29], there are still some valid concerns that to-
tally abandoning the tender point concept would omit ex-
amination of the distinctive ‘hyperalgesia aspect’ of FM 
[13].
Additionally, the 2010 criteria are inherently under- 
representative in regards to the nature of the pain. It only 
incorporates pain regions or distribution and does not con-
sider pain quality and even quantity [3]. Evaluation of pain 
is multidimensional and fewer pain sites (fewer WPI) will 
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not necessarily connote to lower pain significance or im-
pact [38]. So, reliance just on the pain site numbers for 
assessment of pain impact is not the right way to a valid 
diagnosis. 
On the other hand, non-pain symptoms were selected 
from a larger set of symptoms, based on empirical-stat-
istical criteria according to their importance in distinguish-
ing patients with FM from those who are non-FM [29]. This 
larger set did not include symptoms that had been found 
to be essential to FM recognition, for example, stiffness, 
balance, tenderness to touch, environmental sensitivity, 
and invalidation [3,29,31]. 
Ultimately, no criteria can translate a real under-
standing of patient’s symptoms. Comprehension of this 
fact is more important and perplexing since all the diag-
nostic methods of assessment are subjective.
The misclassification rate of the criteria was sig-
nificant among different populations [39-44], especially 
when it was applied to the patients with regional pain dis-
orders in tertiary pain clinics [13]. These observations lead 
to the revision of the 2010 ACR criteria and to developing 
the 2016 modified criteria. The researchers attempted to 
impose the requirement of a meeting of widespread pain 
criterion, such as the 1990 criterion but with caution to 
take away the restrictions of the 1990 criterion [30]. It 
seems that it is time to criticize changing the criteria. Has 
changing or revising the criteria over the past decades 
satisfied researchers or clinicians for making a valid diag-
nosis of FM? The answer is probably “no”. Contrary to the 
declared claim of these criteria, they are not simple and 
practical for clinical use. 
Most practitioners don’t use any criteria for FM diag-
nosis in the clinical settings [2,17]. This may be related to 
the arbitrary nature of these criteria or the criteria’s limi-
tations in coverage of all FM characteristics. It seems they 
are not representative of the multidimensionality and com-
plexity of the nature of FM. So, although the existing cri-
teria can be useful in the recognition of FM, especially for 
research purposes, they are not able to replace the discre-
tionary and holistic eye of expert practitioners. 
6. Labeling of FM diagnosis
FM is a real but untenable diagnosis [34]. Diversity of 
symptoms and phenotypes even in one patient may lead 
to numerous labels over time by medical care providers 
[6,16]. Furthermore, medicalization and a diagnostic ex-
pansion in a population with mild symptoms raise serious 
concerns about FM labeling. In developed countries, FM 
patients often take an active role in their diagnosis [17]. 
It is not uncommon to see self-diagnosis of FM [21]. The 
agency of social and electronic media and support groups 
extend this concept [35,36]. The existing data make clear 
that both under- and over-labeling can lead to personal 
and societal burdens with respect to economic and clinical 
aspects [16]. So, to return to the statement that “no one 
has FM until it is diagnosed and labeled”, it is clear that 
a cautious and holistic approach must be emphasized in 
regard to patients with suspicious FM. 
Modern medicine has empowered societies, physicians, 
and patients with vast increases in access to medical in-
formation, investigations, and with the ability to have more 
options about diagnoses and treatments [45]. However, it 
might be thought that little has changed after many years 
of research on FM diagnosis or treatment. Here, there is 
a quote to Frederick Wolfe: “A kind, conscientious physi-
cian treating a FM patient in 1980 or 1990 will have done 
as well as the 2016 health workers with access to all of 
the new publications and expensive if not very efficacious 
medications” [46]. 
CONCLUSIONS
Precise fibromyalgia diagnosis may be elusive. It seems 
that the meaning of FM symptoms and the conceptualiza-
tion of patients’ complaints in a logical manner needs to 
challenge all of experience and discretion of practicing 
physicians. This means that such logical and complex di-
agnostic challenges cannot be placed into the limited ca-
pacity of FM criteria. 
Although these criteria are the only current methods 
which can be used for classification of FM patients in sur-
veys, research, and clinical settings, there are several key 
pieces missing in the fibromyalgia diagnostic puzzle, such 
as invalidation, psychosocial factors, and heterogeneous 
disease expression. 
Deciding if the patient labeled as having FM or not, 
and also evaluation of the FM patient for disease impact 
require a meticulous and discretionary approach to FM. It 
is better to see FM as a whole, and not as a medical spe-
cialty or constructional scores.
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